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ABSTRACT While progress has been made in characterizing humoral immunity to
Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell re-
sponses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T
cells responding to ZIKV and address the critical question of whether preexisting
dengue virus (DENV) T cell immunity modulates these responses. We find that mem-
ory T cell responses elicited by prior infection with DENV or vaccination with tet-
ravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This
cross-reactivity is explained by the sequence similarity of the two viruses, as the
ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly
conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences
the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute
phase of infection are detected earlier and in greater magnitude in DENV-immune
patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the
convalescent phase in DENV-naive donors but declines in DENV-preexposed donors,
compatible with more efficient control of ZIKV replication and/or clearance of ZIKV
antigen. The quality of responses is also influenced by previous DENV exposure, and
ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated
granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV
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structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell
responses, whereas DENV T cell epitopes are found primarily in nonstructural pro-
teins.
IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preex-
isting DENV T cell immunity modulates Zika T cell responses is of great relevance, as
the two viruses often cocirculate and Zika virus has been spreading in geographical
regions where DENV is endemic or hyperendemic. Our data show that memory T
cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides
and that DENV exposure prior to ZIKV infection influences the timing, magnitude,
and quality of the T cell response. Additionally, we show that ZIKV-specific responses
target different proteins than DENV-specific responses, pointing toward important
implications for vaccine design against this global threat.
KEYWORDS ZIKV, DENV, T cells, heterologous immunity, cross-reactivity,
immunodominance
The pandemic rise of Zika virus (ZIKV) has recently commanded the attention of thegeneral public and medical research community alike (1–4).
ZIKV is a flavivirus most closely related to dengue virus (DENV) (5, 6) but also related
with Japanese encephalitis virus (JEV), West Nile virus (WNV), and yellow fever virus (YF),
all of which are transmitted primarily by mosquitoes (7). Understanding host protective
immunity to this virus is critical for the design of optimal vaccines, but little is currently
known about the immune responses to ZIKV in humans since infections with ZIKV have
not been frequent in the past (8, 9). This is in contrast to a substantial wealth of
information related to T cell immunity against the closely related DENV (10–12).
In the case of DENV, CD8 T cell responses mostly target nonstructural (NS) proteins,
such as NS3, NS4B, and NS5, while CD4 T cell responses are focused on the C, E, and NS5
proteins, even though serotype-specific differences have been noted (10, 13–16). The
main protein targets of CD4 and CD8 T cell immunity are presently unknown for ZIKV.
This dearth of information is a severe knowledge gap, as robust T cell responses may
be required for optimal ZIKV vaccine efficacy (9).
The issue of potential ZIKV and DENV cross-reactivity is of relevance for develop-
ment of both diagnostic tests and vaccines. ZIKV and DENV have significant sequence
similarity and share the same arthropod host, and the geographic range of ZIKV
overlaps largely with areas where DENV is endemic or hyperendemic (6, 17). The
concomitant cocirculation of DENV and ZIKV represents yet another biomedical chal-
lenge, since this phenomenon of common dual exposure increases the potential for
cross-reaction. Serological cross-reactivity has been addressed by several reports (18–
23). However, it is currently unknown to what extent ZIKV and DENV cross-react with
each other at the level of T cell immunity.
According to the well-established phenomenon of heterologous immunity (24, 25),
it is possible that preexisting DENV immunity will affect T cell responses to ZIKV and
hence influence the dynamics and severity of ZIKV epidemics. Importantly, previous
DENV infection can in some instances increase severity of a second DENV infection with
a heterologous serotype, likely through antibody-dependent enhancement (ADE) of
infection and disease (26). In the phase IIb/III clinical trials of the first licensed tetrava-
lent dengue vaccine, increased vaccine efficacy in DENV-preexposed as opposed to
DENV-naive vaccinees was observed, suggesting a protective role of preexisting cross-
reactive DENV-specific T cells that are boosted upon vaccination (9). Thus, it is also
possible that preexposure to either ZIKV or DENV infection will influence the disease
course following infection with the other virus in either a favorable or detrimental
fashion. For all these reasons, it is necessary to gain insight into human T cell responses
to ZIKV.
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RESULTS
DENV T cell responses are cross-reactive with ZIKV peptides. To address the
interplay between DENV- and ZIKV-specific T cell responses, we studied HLA-typed
peripheral blood mononuclear cell (PBMC) donations from Sri Lanka obtained between
2010 and 2016. We also studied PBMC from Nicaraguan donors obtained between 2010
and 2014, thus preceding the current ZIKV epidemic (10, 27, 28). To study CD8
responses, we selected nine DENV-positive donors who had been infected by DENV
multiple times (secondary infections) based on serum neutralization titers and whose
samples showed appreciable ex vivo responses to a pool of previously defined CD8
DENV epitopes (CD8-megapool) (28). A similar approach was used for CD4 responses,
retrieving 5 DENV-positive donors with ex vivo responses to a previously defined DENV
CD4-megapool (11). As negative controls, we used PBMC from donors who were DENV
negative from the same sites.
We tested PBMC from these groups for reactivity against ZIKV peptides in ex vivo
IFN- enzyme-linked immunosorbent sport (ELISPOT) assays. In the case of CD8 T cell
responses (HLA class I), we tested panels of ZIKV-derived peptides predicted to bind
each donor’s HLA molecules (10). HLA restrictions were assigned based on testing short
9mers and 10mers that are predicted to bind with high affinity to the HLA allotypes of
the responding donors. In the case of CD4 T cell responses (HLA class II), we tested a
panel of 684 overlapping peptides spanning the entire ZIKV proteome. CD8-depleted
PBMCs were used in these experiments to avoid inadvertently identifying CD8 epitopes
nested in the 15mer peptide tested. In both cases, peptide pools were tested and the
total reactivity observed in each donor was recorded. The peptide sets used in this
study are summarized in Table 1.
As expected for CD8, T cells from the DENV-negative donors did not respond to
either the previously defined DENV epitopes or to the ZIKV peptides. The cells were
viable and responsive to stimulation, as shown by vigorous responses to phytohem-
agglutinin (PHA) mitogen stimulation. Interestingly, CD8 T cells from one-third of the
DENV-positive donors recognized ZIKV-derived peptides (Fig. 1A). Higher levels of
cross-reactivity emerged from the study of the CD4 T cells, as ZIKV-derived peptides
were recognized by CD4 T cells from 4 out of 5 DENV-positive individuals (Fig. 1B).
In a further series of experiments, we analyzed responses from two additional
cohorts of donors, a cohort of donors recently vaccinated with a tetravalent dengue
attenuated vaccine (TDLAV) and a control cohort of donors negative for responses to
DENV and other flaviviruses provided to the University of Vermont clinical site. Re-
sponses against the DENV CD8-megapool and pools of ZIKV predicted peptides match-
ing the HLA A and B alleles expressed in each donor were tested in IFN-gamma (IFN-)
intracellular cytokine staining (ICS) assays (Fig. 1C). CD8 T cells from the flavivirus-
negative donors did not respond to either the previously defined DENV epitopes or the
ZIKV peptides. In contrast, CD8 T cells from TDLAV donors recognized, as expected, the
DENV CD8-megapool as well as more than 50% of the cases of the ZIKV-derived
peptides. In conclusion, analysis of ex vivo responses of ZIKV-naive and DENV-positive
donors revealed substantial cross-reactivity to ZIKV-derived peptides.
Identification of ZIKV epitopes cross-reactive with DENV responses. Individual
epitopes were mapped in representative cases. Where sufficient cell numbers were
available, positive pools were deconvoluted to identify ZIKV-specific epitopes across
the ZIKV genome, including all structural and nonstructural (NS) proteins. The mapping
of CD4 and CD8 responses was performed by sequential testing of pools and decon-
volution to identify the positive peptides (Fig. 2A). The HLA-B*35:01 CD8 epitope
encoded by ZIKV NS32867–2876 was recognized by PBMC from a DENV-positive Nicara-
guan donor (Fig. 2B). This epitope was found to be highly similar (a single Y-to-F
substitution) in DENV1 to -4 serotype consensus sequences obtained as previously
described (10). A Sri Lankan donor recognized the B*07:02 ZIKV NS31725–1734 epitope
(Fig. 2C). The same epitope was also recognized by a different DENV-positive Sri Lankan
donor (Fig. 2D). The identical sequence was found in DENV2, -3, and -4.
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In the case of CD4 (Fig. 2E), the ZIKV NS52986–3000 epitope, 100% conserved in
DENV1 to -4 sequences, was recognized by PBMC from a DENV-positive Sri Lankan
donor. PBMC from a Nicaraguan donor recognized the ZIKV NS1986–1000 epitope (Fig.
2F). Here, the recognized 15mer contained a core NS1989–998 sequence that was also
highly conserved in all DENV serotypes, with A-to-S and M-to-L conservative substitu-
tions. A different pattern was observed for the ZIKV E486–500 epitope, which was
recognized by PBMC from a different DENV-positive Nicaraguan donor (Fig. 2G). In this
case the most homologous 9mer (sequence LYYLTMNNK) shared only 4 identities with
DENV1 sequences and had 2 conservative (L to M and N to E) and 3 semiconservative
(Y to V, Y to L, and K to N) substitutions. Additional sequence homology analysis using
GenBank sequences did not reveal any sequences with higher homology from other
common flaviviruses, such as JEV, WNV, DENV, and YFV.
In conclusion, in 5 out of 6 instances the cross-reactivity from the DENV-positive
(and presumably ZIKV-negative) donors was directed to ZIKV sequences found to be
identical to or highly conserved with sequences in DENV serotypes.
Recruitment of donor cohorts differing in ZIKV and DENV preexposure status.
To address the effect of preexisting immunity on T cell responses to secondary flavivirus
infection, we investigated six donor groups, namely, ZIKV acute, convalescent, and
negative, and for each of these cohorts we further subdivided our cohorts into
DENV-positive and -negative individuals. For the purpose of classification in the various
cohorts, the following criteria were used. Infection with ZIKV was confirmed using
reverse transcription-PCR (RT-PCR) performed on acute infection samples, as described
in more detail below. Depending on the time of sample collection after the onset of
TABLE 1 ZIKV peptides used in this study
Allele
No. of peptides positive for:
C pr M E NS1 NS2A NS2B NS3 NS4A 2K NS4B NS5 Total
ZIKV predicted peptide set composed of
9- and 10mer peptides
HLA-A*01:01 0 10 5 21 6 8 6 21 4 0 17 38 136
HLA-A*02:01 7 0 6 20 3 23 5 17 10 3 26 16 136
HLA-A*02:03 9 0 6 16 3 23 8 20 9 4 23 15 136
HLA-A*02:06 4 2 2 14 6 25 5 17 17 6 25 13 136
HLA-A*03:01 12 4 4 11 10 17 4 22 5 0 8 39 136
HLA-A*11:01 14 6 2 11 9 6 7 23 6 0 11 41 136
HLA-A*23:01 5 2 4 20 7 7 1 21 7 0 21 41 136
HLA-A*24:02 4 3 4 16 5 9 2 16 7 0 24 46 136
HLA-A*26:01 6 5 1 15 6 10 15 16 9 3 17 33 136
HLA-A*30:01 9 3 1 18 16 8 3 26 3 0 10 39 136
HLA-A*30:02 1 10 5 17 11 2 8 24 1 0 21 36 136
HLA-A*31:01 10 3 8 8 18 11 2 25 1 0 5 45 136
HLA-A*32:01 6 3 6 21 9 18 6 16 7 1 11 32 136
HLA-A*33:01 9 1 5 6 15 12 3 22 2 0 5 56 136
HLA-A*68:01 9 4 5 12 13 8 3 35 3 0 7 37 136
HLA-A*68:02 7 5 5 17 6 11 7 18 8 5 22 25 136
HLA-B*07:02 4 2 6 12 15 16 5 35 6 2 11 22 136
HLA-B*08:01 11 4 2 13 13 16 0 24 10 0 7 36 136
HLA-B*15:01 4 7 7 18 6 12 7 17 6 1 23 28 136
HLA-B*35:01 4 5 3 14 5 12 9 23 7 2 26 26 136
HLA-B*40:01 2 4 4 17 17 4 8 25 10 0 6 39 136
HLA-B*44:02 1 4 1 15 18 3 7 32 7 0 5 43 136
HLA-B*44:03 3 3 2 14 20 3 7 33 7 0 4 40 136
HLA-B*51:01 4 0 8 13 6 19 9 17 9 5 17 29 136
HLA-B*53:01 6 3 2 18 13 12 6 18 8 2 17 31 136
HLA-B*57:01 3 5 4 15 16 12 3 13 4 0 13 48 136
HLA-B*58:01 7 1 5 17 16 14 3 11 5 0 11 46 136
Total 161 99 113 409 288 321 149 587 178 34 393 940 3672
15mer peptides spanning the ZIKV polyprotein
HLA class II 25 18 15 100 70 46 26 123 25 5 50 180 683
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symptoms or ZIKV RNA-positive blood donation, samples were classified as either acute
or convalescent, as described in more detail in Materials and Methods. ZIKV negativity
was inferred based on donations being obtained before or outside the area affected by
the epidemic. DENV-positive or -negative status was determined on the basis of IgG
status at the time of clinical presentation or blood donation or, in the case of the
Nicaraguan samples, from documented history of DENV infection in the longitudinal
cohort study. The subjects studied spanned a very diverse breadth of ethnicities and
clinical sites, including Brazil (Rio de Janeiro and Sao Paulo), Nicaragua, Puerto Rico,
Mexico, returned U.S. travelers, and a U.S. flavivirus-negative cohort. The general
features of the subjects are detailed in Table 2. The relative proportion of females across
all cohorts was 60%, and the average age was 34 years (range, 3 to 70 years).
ZIKV-specific responses are modulated by previous DENV exposure. We next
compared ZIKV T cell reactivity in the subjects described above as a function of ZIKV
status (i.e., negative, acute infection, or convalescent status) and also considering prior
DENV infection as a variable. To assess T cell reactivity, we devised a strategy to account
for the fact that in most cases the amount of PBMC was limiting. Accordingly, the
FIG 1 Ex vivo reactivity to ZIKV-derived peptides and previously defined DENV epitopes in DENV-positive and -negative donors and DENV vaccines. CD8 (A)
and CD4 (B) T cell reactivity to DENV epitopes and ZIKV peptides in ELISPOT ex vivo experiments are shown for DENV-positive (red) or -negative (black) donors.
Responses were expressed as the number of IFN--secreting cells per 106 PBMC and were considered positive if the net SFC/106 PBMC was 20, had a
stimulation index of 2, and had a P value of 0.05 in a t test or in a Poisson test comparing replicates with those from the negative control. Donors with
PHA values of 250 SFC per 106 PBMC have been excluded from the analysis. Data are expressed as geometric means with 95% CI. (C) CD8 T cell reactivity
to a DENV megapool and ZIKV HLA-restricted pools in ICS experiments are shown in DENV vaccinees (green) and compared with flavivirus-naive donors (black).
Data are expressed as averages  standard deviations (SD) of the percentages from CD3 CD8 IFN- cells.
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overlapping 15mers spanning the entire ZIKV proteome were divided into 10 pools
corresponding to the 10 encoded ZIKV proteins. ICS assays and CD8/CD4 gating
allowed assessment of CD8 and CD4 responses in parallel without the need to know the
HLA phenotype of the donor. All of the ZIKV CD8 responses in ZIKV samples have been
assessed using these pools of overlapping peptides and gating on CD8 responding T
cells in the ICS assay. In a few instances where the number of PBMC available from each
donor did not allow testing of all pools, a factorial design was utilized: while not all
pools were tested in all donors, all pools were tested in the same number of donors.
Whenever sufficient cell numbers were available, positive pools were deconvoluted and
specific epitopes identified. Overall, PBMC from 17 to 33 donors/patients were tested
for each of the different categories (Table 3).
FIG 2 Mapping of CD8 and CD4 cross-reactive DENV-ZIKV T cell epitopes. (A) Example of the mapping strategy. CD8 (B to D)- and CD4 (E to G)-restricted
epitopes were mapped by peptide deconvolution in ELISPOT ex vivo experiments in individual donors. ZIKV epitope sequences were aligned with consensus
sequences of DENV1, DENV2, DENV3, and DENV4 serotypes. Amino acid mismatches between the ZIKV sequence and the DENV consensus sequences are shown
in red.
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The frequency of ex vivo responses in ZIKV-infected patients was 30 to 40% for both
CD4 and CD8 responses, with the exception of CD8 responses in acutely infected
donors, which were detected in approximately 90% of the cases (Fig. 3A and D, left).
Marginal CD8 responses to the ZIKV peptides were noted in the case of the ZIKV-
negative, DENV-negative donors (Fig. 3A). However, ZIKV-negative, DENV-positive do-
nors showed appreciable reactivity both in terms of increased frequency and magni-
tude of responses, confirming a degree of T cell cross-reactivity between the DENV-ZIKV
responses observed above (Fig. 1 and 2). In the acute ZIKV-positive/DENV-positive
donors, CD8 responses to ZIKV peptides were of significantly higher magnitude than
those of acute ZIKV subjects who were DENV negative (Fig. 3B and C). After ZIKV
convalescence, the CD8 responses to ZIKV-restricted peptides were still elevated com-
pared to those of ZIKV-negative donors but were not significantly different by DENV
serostatus (Fig. 3B and C). The pattern of CD4 responses to ZIKV-restricted class II
peptides was remarkably similar with regard to ZIKV acute and convalescence phases
and impact of DENV seropositivity, with trends for ex vivo ZIKV T cell responses being
delayed in DENV-negative donors and lower frequency and magnitude of responses
observed with respect to the CD8 counterpart (Fig. 3D to F).
Different proteins are targeted by ZIKV versus DENV immunity. We next deter-
mined whether DENV serostatus affected the antigenic targets of ZIKV-reactive T cells
across the ZIKV polyprotein. A breakdown of ZIKV CD8 responses in acute and conva-
lescent ZIKV-positive donors (combined in this plot) as a function of the antigen
targeted is presented in Fig. 4. In the case of ZIKV-specific CD8 responses in DENV-
negative donors, 57% of the response was directed against structural proteins (Fig. 4A).
In the context of a previous DENV exposure, however, only 30% of the ZIKV-specific
responses were directed against structural proteins (Fig. 4B). This can be compared to
historical data regarding DENV responses from presumably ZIKV-negative donors (since
samples were collected prior to the 2015-2016 ZIKV epidemic), where only 14.9% of the
response was directed against structural proteins (10). Thus, the CD8 response to ZIKV
is more focused on structural proteins than on nonstructural proteins by DENV-specific
TABLE 2 General features of ZIKV-infected cohorts
Source Country
No. of
patients Agea (yr)
Sex
(% female) % DENV
University of São Paulo Brazil 7 45 (25–61) 85 85
Fundação Oswaldo Cruz Brazil 12 35 (22–60) 20 100
PDCS Nicaragua 14 7 (3–14) 78 14
REDSIII Puerto Rico/USA 20 46 (21–70) 35 85
Universidad Veracruzana Mexico 19 38 (6–69) 63 26
University of North Carolina Unites States 8 37 (18–53) 71 50
University of Miami United States 2 29 (26–32) 100 50
Vanderbilt University United States 9 42 (19–62) 56 11
National Institutes of Health United States 7 29 (26–40) 42 71
Overall 98 34 (3–70) 60 54
aExpressed as the average age of the cohort (range).
TABLE 3 Donors tested in each category
No. of samples ZIKV statusa DENV statusb Country of origin
18 Acute Pos. Brazil/Mexico
17 Acute Neg. Nicaragua/Mexico
33 Convalescent Pos. Brazil/U.S. travelers/blood bank donors
30 Convalescent Neg. U.S. travelers/blood bank donors
20 Neg. Pos. Nicaragua/Sri Lanka
20 Neg. Neg. USA
aInfection with ZIKV was confirmed by RT-PCR. ZIKV-negative (Neg.) samples were collected before the onset
of the ZIKV epidemic.
bPrevious exposure to DENV was determined by the presence of detectable DENV-specific IgG titers. Pos.,
positive.
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T cells. Nonetheless, DENV preexposure modulates the ZIKV-reactive immunodomi-
nance pattern for CD8 cells, resulting in broad recognition across the ZIKV proteome.
In the context of CD4, responses were directed in approximately equal proportions
against structural and nonstructural proteins (Fig. 4B). Differences between DENV and
ZIKV patterns of immunodominance were not prominent, which was not surprising,
since, according to published data, the DENV-specific response is already focused
almost equally (50%) on structural and nonstructural proteins (11). In the present study,
the fraction of ZIKV-specific responses directed against structural proteins was 58% or
67% for DENV-negative subjects and DENV-positive, ZIKV-positive donors, respectively
(Fig. 4C and D).
As described above, whenever possible, peptide pools were deconvoluted and
specific epitopes mapped using the same mapping approach as that previously shown
in Fig. 2A. Two ZIKV NS5 epitopes (NS52819–2828 and NS52868–28876), both predicted to
be restricted by HLA B*35:01, were recognized in an HLA-matched DENV-positive donor
(Fig. 5A and B). One of these epitopes was independently identified in a DENV-positive,
ZIKV-negative donor (Fig. 2B). In both cases, the ZIKV epitope differed from DENV
sequences by a single conservative substitution. A second DENV-positive donor re-
FIG 3 Ex vivo reactivity of ZIKV donors to ZIKV peptides. CD8 (A to C) and CD4 (D to F) ZIKV-restricted responses in ZIKV-negative, acute, and convalescent
donors are shown in intracellular cytokine experiments. Each group is further divided in DENV positive (red) or negative (black). Each donor has been tested
with at least 5 protein pools (C-NS2A or NS2B-NS5) or the full set of protein pools depending on the availability of cells (A, B, D, and E). Each data point
represents the response of a single donor if all 10 proteins were tested or the combined response of two donors tested with the two different sets of 5 protein
pools. Panels C and F show all of the responses against individual pools regardless of the donor tested. Statistical significance for differences in frequency of
responders (left) was performed using a Fisher test. The magnitude of responses (center and right) is expressed as geometric means with 95% CI, and statistical
analyses were performed with Mann-Whitney U test.
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sponded to the ZIKV ENV719–728 epitope (predicted B*40:01 restriction), which differs
from DENV3 sequences by a single conservative substitution (Fig. 5C). Another E
protein epitope was identified in the same donor (E481–495; restricted by HLA A*01:01),
which in this case had more limited homology to DENV sequences (Fig. 5D).
Independent experiments showed that the very same ZIKV E485–493 HLA A*01:01
epitope also was recognized in a DENV-negative subject (Fig. 5E and M. J. Ricciardi et
al., submitted for publication). Interestingly, longer versions of this peptide were not
recognized. It is possible that both 9mers and 10mers bind with high affinity but in
somewhat different registers. Additional epitopes recognized in DENV-negative donors
were mapped to a ZIKV C23–32 epitope restricted by HLA A*03:01, showing again limited
homology to DENV sequences, and two additional ZIKV NS3 epitopes restricted by HLA
FIG 4 Immunodominance pattern of CD8 and CD4 responses against ZIKV-derived peptides. ZIKV CD8 (A and B) and CD4 (C and D) responses to 10 ZIKV
proteins are shown in ZIKV-positive and DENV-negative subjects (A and C, left) or DENV-positive subjects (B and D, right). Structural (C, prM, and E) and
nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins are divided by a dotted line, and their magnitudes in percentages are shown in each graph.
The total magnitude of the responses has been calculated and the resulting percentage of responses for structural and nonstructural proteins shown in the
upper left and right, respectively, of each panel. Data are expressed as geometric means with 95% CI.
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B*0801 and B*41:02 (Fig. 5F to H). Additionally, we selected two ZIKV peptides,
TPYGQQRVF and APTRVVAAEM, which were recognized by DENV-seropositive donors
(Fig. 2A to C), and synthesized the corresponding DENV peptides. These peptides then
were tested in parallel with the original ZIKV peptides with PBMC from the donor
originally utilized to map the responses in standard IFN- ELISPOT assays. We also
tested the ZIKV ENV GLDFSDLYY epitope, defined in a DENV-seronegative donor (Fig.
5E), and tested the corresponding DENV peptides in parallel with the originally iden-
tified ZIKV peptide. The ZIKV TPYGQQRVF and APTRVVAAEM peptides, as well as the
corresponding highly homologous DENV TPFGQQRVF and APTRVVASEM peptides,
were recognized by the DENV-seropositive donor with comparable magnitude. In
contrast, the ZIKV Env GLDFSDLYY, but not the fairly discordant corresponding DENV
epitopes GLDFNEMVL and GIDFNEMVL (amino acid residues that differ from those of
the ZIKV original epitope are in boldface), were recognized by the DENV-seronegative
donor response (Table 4).
Phenotype analysis of CD8 T cells responsive to ZIKV peptides. To gain further
insights into the potential biological significance of these patterns of reactivity, we
determined cell surface phenotypes of the CD8 T cells producing IFN- in response to
the ZIKV peptide pools. As expected (Fig. 6A), these cells were predominantly T effector
memory (TEM) (CCR7 CD45RA; approximately 60% on average) and terminally
differentiated effector memory (TEMRA) (CCR7 CD45RA; approximately 30% on
average). Approximately 50% of the IFN- CD8 T cells were tumor necrosis factor
alpha positive (TNF-) compared to less than 1% of the IFN- cells (Fig. 6B), thus
establishing that a large fraction of the responding cells are polyfunctional. Similar
patterns were observed for ZIKV DENV and ZIKV DENV donors in terms of both
memory phenotypes and polyfunctionality.
FIG 5 Mapping of CD8 ZIKV epitopes in ZIKV-positive donors. ZIKV-restricted epitopes mapped by peptide deconvolution in ELISPOT ex vivo experiments in
DENV-positive (A to D) or DENV-negative (E to H) individuals. ZIKV epitope sequences were aligned with consensus sequences of DENV1, DENV2, DENV3 and
DENV4 serotypes. Amino acid mismatches between the ZIKV sequence and the DENV consensus sequences are shown in red. Boxes indicate the optimal epitope
restricted by the specific HLA phenotype present in this donor.
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In contrast, significant differences were seen between ZIKV DENV and ZIKV
DENV donors when the granzyme B and PD1 markers were considered. The expres-
sion of granzyme B in CD8 T cells from ZIKV DENV was not significantly increased in
IFN- cells compared to the background level of approximately 30% seen in IFN-
cells, while in the case of ZIKV DENV donors approximately 80% of the IFN- cells
FIG 6 Phenotype characterization of CD8 ZIKV-specific immune responses in ZIKV-positive donors. Memory phenotype (A) and
polyfunctionality (B to D) of ZIKV CD8 T cells were compared in ZIKV-positive, DENV-negative (black) donors and ZIKV-positive,
DENV-positive (red) donors. (A) Average percentage of memory phenotype populations (naïve, CD45RA CCR7; central memory,
CD45RA CCR7; effector memory, CD45RA CCR7; and TEMRA, CD45RA CCR7) in CD8 ZIKV-specific IFN--producing cells. IFN-
(oblique lines) and IFN- (blank pattern) CD8 T cells were analyzed for the coexpression of TNF- (B), granzyme B (C), and PD1 (D). Data
were expressed as averages  SD of the percentage of CD3 CD8 cells. Statistical analysis was performed with Mann-Whitney U test.
*, P  0.05; **, P  0.01; ***, P  0.005; ****, P  0.001.
TABLE 4 Testing of DENV peptides for ZIKV NS52868–2876, NS31725–1734, and E485–493
peptides
Donor
DENV
status
ZIKV
status Protein Source
Peptide
sequence
SFC/106
PBMCa
GN0101 Pos. Neg. NS52868–2876 ZIKV TPYGQQRVF 353 240
DENV1–4 TPFGQQRVF 366 120
GS0157 Pos. Neg. NS31725–1734 ZIKV APTRVVAAEM 330 75
DENV1 APTRVVASEM 219 64
2894 Neg. Pos. E485–493 ZIKV GLDFSDLYY 287 50
DENV1–3 GLDFNEMVL 0
DENV4 GIDFNEMVL 0
aAverages and standard deviations of net responses from 6 to 9 independent wells for donors GN0101 and
GS0157 and 3 independent wells for donor 2894.
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were also granzyme positive (Fig. 6C). Similarly, PD1 was only mildly expressed in
IFN- cells from ZIKV DENV donors, while on average 60% of the ZIKV DENV
IFN- cells also upregulated PD1 (Fig. 6D). These data indicate that DENV preexposure
affects not only the quantity but also the quality of responses observed following ZIKV
infection.
DISCUSSION
We report the first characterization in humans of both ZIKV-specific and ZIKV/DENV
cross-reactive T cell responses and the influence of DENV serostatus on T cell immunity
to ZIKV. Our study established three main points. First, preexisting T cell responses
against DENV recognize peptide sequences located in the ZIKV proteome. Second,
cross-reactivity is immunologically consequential, as DENV-positive individuals at the
time of ZIKV infection respond more strongly to ZIKV both in terms of CD4 and CD8 T
cell responses. Third, patterns of immunodominance are different in the case of DENV
and ZIKV infection, with ZIKV-specific CD8 T cell responses predominantly targeting
structural proteins such as E, prM, and C. Our study involves samples form ZIKV-infected
donors derived from a variety of different geographical locations, including the U.S.
mainland (travelers returning from affected areas), Puerto Rico, Brazil, Nicaragua, and
Mexico. As such, we believe that the pattern of responses we observed is of general
relevance and not limited to a specific population or clinical context. In the present
study, we did not isolate representative viruses from the different cohorts and compare
the sequences in terms of the percentage of similarity/differences to the peptide
libraries used. Thus, it is possible that intra-ZIKV sequence variation influences some of
the results, which should be interpreted with this caveat in mind.
We established that DENV-specific memory T cells recognize peptide sequences
located in the ZIKV proteome. This point was established with a separate set of PBMC
donations obtained in Sri Lanka, where ZIKV has not been reported, and from Nicara-
gua, collected between 2010 and 2014, before the introduction of ZIKV into the
country. In this study, we did not test recognition of the DENV peptides corresponding
to the ZIKV epitopes. We note this limitation in our interpretation, as, for example,
recognition of the corresponding DENV peptide could be much higher than that for the
ZIKV peptide. The molecular basis of this cross-reactivity was established by mapping
several different CD4 and CD8 epitopes. These epitopes represent the first mapping of
DENV/ZIKV cross-reactive epitopes in humans, and in most cases the cross-reactivity
could be explained by identity or high similarity to sequences previously identified in
one or more DENV serotypes. This finding was predicted by previous analysis con-
ducted by the IEDB analysis resource (6) and by a recent study utilizing HLA transgenic
mice (29). Nonetheless, identification of specific sequences here allows for a compre-
hensive assessment of whether the cross-reactivity is focused on regions that are highly
conserved. Most importantly, we demonstrate that DENV-specific CD8 responses in-
duced by TDLAV vaccination recognize ZIKV-derived peptides. This cross-reactivity
indicates a potential for the TDLAV to provide some degree of protection against ZIKV
infection.
An average homology level of 77% was observed between the sequences of DENV
and ZIKV cross-reactive epitopes (defined as ZIKV sequences recognized in DENV-
positive donors) compared with an overall 56% level of homology detected when the
overall sequences of ZIKV and DENV proteomes were compared (Table 5). We conclude
that sequential exposure to DENV and ZIKV sequences preferentially expands responses
against conserved sites between the viruses. Similar observations were made in previ-
ous studies that showed that secondary DENV infections are associated with preferen-
tial recognition of epitopes conserved among different DENV serotypes, showing that
secondary DENV infections are associated with preferential recognition of epitopes
conserved among different DENV serotypes (10). Also, sequential exposure to different
DENV serotypes in animal DENV models results in expansion of T cells recognizing
cross-reactive epitopes (16, 30). It would have been interesting to examine if primary
versus secondary DENV infection or the time interval between DENV and ZIKV infection
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influences T cell responses to ZIKV peptides. However, this information is not available
to us from all different sites, and an analysis of this variable could be addressed in future
studies specifically designed to examine this issue.
It is also noteworthy that three out of 11 of the identified epitopes were identified
in multiple independent donors (ZIKV NS31725–1734, NS52868–2876, and E485–493). Albeit
based on a limited number of subjects, these results indicate that ZIKV responses are
associated with strong immunodominance of particular epitopes.
In addition, NS52868–2876 was identified in DENV ZIKV and DENV ZIKV individ-
uals, but no reactivity was detected in pools containing this peptide in DENV ZIKV
donors. Conversely, ZIKV E485–493, with a lower homology level with DENV, was
identified in DENV ZIKV and DENV ZIKV individuals but not in DENV ZIKV
donors.
Significant differences in frequency or magnitude of T cell responses to ZIKV
peptides in PBMC from ZIKV DENV donors compared with ZIKV DENV donors
were detected in the acute phase of infection with ZIKV. This parallels similar obser-
vations made in terms of antibody responses that showed that ZIKV/DENV cross-
reactivity is most readily detected close to infection and wanes afterwards (31). We also
find that DENV preexposure influences ZIKV responses. This could be understood in the
context of the well-recognized phenomenon of heterologous immunity (24, 25). Spe-
cifically, ZIKV-specific T cell responses for both CD4 and CD8 T cells develop more
rapidly in DENV-positive individuals and are already apparent in the acute phase of the
disease. These responses subside at convalescence but remain elevated compared to
those in ZIKV-negative individuals. The percentage of subjects with confirmed ZIKV
infection who showed a positive T cell response (Fig. 3A and D) is relatively low,
consistent with a primary infection and with ZIKV being associated, in most cases, with
a milder clinical presentation than DENV (16). This pattern is reflective and characteristic
of the differences in a primary compared to a classic secondary response (32). Here, we
demonstrate how prior DENV infection alters ZIKV-specific immune responses, and we
provide the first evidence that prior DENV infection leads to stronger and faster
responses, thus providing evidence of a biological outcome. This is the first evidence in
humans that previous exposure to dengue virus can influence subsequent infection
with ZIKV by mounting a cross-reactive memory T cell response against ZIKV. Recent
data in HLA transgenic mice demonstrated that ZIKV challenge following immunization
of mice with ZIKV-specific and ZIKV/DENV cross-reactive epitopes elicited CD8 T cell
responses that reduced infectious ZIKV levels, and CD8 T cell depletions confirmed
that CD8 T cells mediated this protection (29). In addition, a recent paper has shown
that Zika virus pathogenesis in rhesus macaques is unaffected by preexisting immunity
TABLE 5 Sequence homology between ZIKV and DENVa
Serotype
Homology (%) to ZIKV
Polyprotein C prM E NS1 NS2A NS2B NS3 NS4A  2k NS4B NS5
DENV1 55 50 43 57 54 30 35 66 43 51 67
DENV2 56 41 41 55 54 27 41 67 52 53 67
DENV3 57 50 42 58 55 29 38 67 39 52 67
DENV4 57 49 47 56 54 34 41 67 44 49 68
Avg 56 47 43 58 55 31 39 67 44 51 67
Avg % of structural proteins 49b Avg % of nonstructural proteins 51b
Avg % of structural proteins
accounting for size
51c Avg % of nonstructural proteins
accounting for size
58c
aHomology analysis between the BeH818995 ZIKV isolate (GenBank accession no. AMA12084.1) and DENV1,
-2, -3, and -4 consensus sequences obtained as previously reported (10, 11).
bAverages of structural and nonstructural proteins were based on averages of the different homology values
in the four DENV serotypes for each protein.
cAverage conservation was determined on a per-residue basis of structural and nonstructural proteins
accounting for size.
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to dengue virus (33). Together, these data underline important implications for ZIKV
vaccine development.
We have previously shown that stronger T cell responses are associated with certain
HLA alleles associated with protection in cases of heterologous infection with DENV,
pointing to a protective effect of these cross-reactive responses (10). Given that the
groups were drawn from different study populations (age and genetic background),
which could influence the magnitude of the T cell responses, further studies will
provide more evidence on the generality of our findings. It remains to be seen whether
this effect will be mimicked by DENV or ZIKV vaccination. Importantly, our data indicate
that DENV preexposure also alters the quality of responses. While no difference was
seen between DENV-preexposed and DENV-naive donors at the level of composition of
memory subsets in the responding cells or the degree of multifunctionality, DENV-
specific CD8 responses from DENV-preexposed donors significantly upregulated gran-
zyme B and PD1, suggesting a more differentiated phenotype, similar to what was
detected in secondary DENV infection (27, 34).
Our data provide an example of adaptive heterologous immunity, where cross-
reactive memory dengue-specific CD8 T cells are enhancing the T cell responses to
ZIKV. At this time, these studies do not yet address whether this will be beneficial in the
majority of cases while at other times it could be detrimental based on the specific
cross-reactive pattern of each patient. However, identifying key cross-reactive epitopes
in humans and demonstrating that they influence the characteristics of the subsequent
T cell response to ZIKV, as this study does, is an important step toward understanding
potential immunopathology in ZIKV infection.
An unexpected result of our analysis is that almost 60% of the ZIKV-specific CD8
responses in ZIKV-positive but DENV-negative individuals are directed against structural
proteins. This is in contrast to the relative paucity of structural protein-directed T cell
responses observed in DENV infection, where only 15% of CD8 T cell responses are
directed against structural proteins (10), even though serotype-specific differences have
been noted (10, 13–16). Interestingly, the percentage of CD8 T cell responses directed
against structural proteins in DENV-positive ZIKV patients is 30%, suggesting that
previous DENV exposure alters the patterns of immunodominance, skewing it toward
a pattern more similar (but still not identical) to that observed in DENV-positive donors
in the absence of ZIKV infection.
The degree of homology (conservation) between NS proteins of DENV and ZIKV is
51%, on average, compared to 49% for structural proteins and 58% compared to 51%
when accounting for size difference, so a higher degree of homology does not itself
drive or focus cross-reactive responses on these antigens. The conclusion that T cell
epitopes for ZIKV and DENV differ in their distribution between structural and non-
structural proteins requires the caveat that this is based on comparing data generated
in separate studies, which have used different methods (e.g., ELISPOT assay versus flow
cytometry). In addition, it cannot be excluded that the strong magnitude of one donor
may have an substantial effect on the percentage of the total response directed toward
nonstructural proteins.
It would have been of interest to determine the number of epitopes detected in the
structural and nonstructural regions on a per-donor basis. This analysis could provide
additional support for the notion that preexisting immunity to DENV broadens recog-
nition across the ZIKV proteome. Due to the small volume of blood samples collected,
we were not able to deconvolute all positive pools to identify the exact epitope. Future
studies where larger amounts of blood are collected will allow us to comprehensively
address this point. It is also worth noting that significant CD8 responses directed
against structural proteins were reported in the case of West Nile and Japanese
encephalitis viruses (35, 36). These two flaviviruses both are associated with neurolog-
ical complications (37). Further, we previously showed in an HLA-transgenic model a
trend toward higher recognition of structural proteins for DENV3 (compared to other
DENV strains) (16), which also was reported previously to be associated with neuro-
logical symptoms (38, 39). Similarly, we have previously shown that human DENV3
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serotype-specific CD8 T cell responses preferentially recognize structural proteins.
Conversely, DENV1 and DENV4 serotypes preferentially recognized nonstructural pro-
teins. Finally, the DENV2 serotype showed a broader recognition of all proteins but still
elicited the strongest CD8 T cell response against nonstructural proteins (28). As no
higher level of homology is observed between ZIKV and DENV3 with respect to the
other DENV serotypes that could explain the preferential recognition of structural
proteins (Table 5), we hypothesize that common processing pathways or similar CD8
T cell elicitation occurs that differs from that of the other DENV serotypes and will need
further investigation.
Mapping of over 10 different ZIKV epitopes suggests that DENV-positive donors
tend to recognize DENV/ZIKV highly conserved epitopes, while DENV-negative subjects
may recognize more divergent targets. On average, 76% homology existed between
DENV and ZIKV sequences among cross-reactive epitopes (defined as ZIKV sequences
recognized in DENV-positive donors), compared with a 55% average level of homology
between DENV and ZIKV sequences at the level of ZIKV epitopes recognized in
DENV-negative donors and an overall 56% level of homology detected when the overall
sequences of ZIKV and DENV proteomes were compared. These results emphasize that
previous exposure to DENV influences the fine repertoire of epitopes being recognized.
It remains to be seen if cross-reactivity of T cells also can be detected between ZIKV and
other related flaviviruses. In the present study, we have not characterized WNV or JEV
exposure. It is possible that cross-reactivity at the T cell level exists between ZIKV and
other more distantly related flaviviruses, and this point will be address in future studies.
In the majority of cases, the degree of homology between ZIKV and DENV was very
high, suggesting that a ZIKV diagnostic assay based on T cell responses is not imme-
diately practical and conversely reemphasizing that DENV preexposure (or vaccination)
might influence ZIKV immunity. Vaccines against ZIKV that are currently under devel-
opment and focus on structural protein antigens rather than live virus may have
logistical (no need for cold chain) and safety (no risk of virulent reversion and safe to
administer to pregnant and immunocompromised patients) advantages; however,
these vaccines may not comprise the full set of antigens required to induce protective
immunity. Our results that approximately 55 to 60% of the ZIKV-specific CD4 and CD8
response is directed against structural proteins is encouraging, in that cellular re-
sponses necessary to directly limit ZIKV infection and support T cell-dependent anti-
body responses may be achievable with vaccine approaches being pursued.
MATERIALS AND METHODS
Human blood samples. All samples were collected after informed consent, and the study was
approved by the La Jolla Institute institutional review board (IRB) committee (IRB number VD-154). An
overview of the clinical and serological characteristics of all ZIKV samples is provided in Table 2. The
sample allocation was provided by collaborators that collected the samples. The investigators were
aware of the group allocation during the experiment and when assessing the outcome. In addition, Table
S1 in the supplemental material provides a summary of the HLA typing data of the PBMC donor, and
DENV infection history was available for all donors analyzed in this study.
Samples from flavivirus-naive controls. Healthy adult male and nonpregnant female volunteers, 18
to 50 years of age, were enrolled from Baltimore, Maryland, Washington, DC, and Burlington, Vermont,
and tested for the presence of serum antibodies to all DENV serotypes, yellow fever virus, West Nile virus,
and St. Louis encephalitis virus, as previously described (40).
Samples from areas where DENV is endemic. Blood donations from healthy adult blood donors of
both sexes between the ages of 18 and 65 years were collected by the National Blood Center, Ministry
of Health, Colombo, Sri Lanka, in anonymous fashion between the years of 2010 and 2016 and processed
at the Genetech Research Institute as previously described (11). Similarly, the National Blood Center (NBC)
of the Nicaraguan Red Cross in Managua, Nicaragua, provided anonymous blood samples collected
between 2010 and 2014, prior to the introduction of ZIKV into the country (16).
Samples from DENV tetravalent vaccination. Healthy donors were enrolled and vaccinated with
TV005, a tetravalent DENV vaccine formulation. Blood samples were collected as a part of phase I clinical
trials (ClinicalTrials registration numbers NCT01506570 and NCT01436422) at the Johns Hopkins
Bloomberg School of Public Health (JHSPH) and at the University of Vermont Vaccine Testing Center and
Center for Immunization, as previously reported (15, 41, 42).
Samples from area where ZIKV is endemic. Blood samples were collected from patients displaying
symptoms of a suspected ZIKV infection in Brazil, Nicaragua, and Mexico. Samples were also collected
from blood donors identified through routine donor screening in Puerto Rico and Florida. Infection with
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ZIKV was confirmed using RT-PCR, as described in more detail below. All samples were screened for
previous DENV exposure by measuring DENV-specific IgG titers and/or neutralizing antibodies or from a
documented history of DENV infection. Depending on the time of sample collection after onset of
symptoms, samples were classified as acute (2 to 14 days postonset of symptoms or hospitalization) or
convalescent (more than 15 days postonset of symptoms). Blood samples collected within the Recipient
Epidemiology and Donor Evaluation Study III (REDSIII) were collected approximately 3 months following
ZIKV RNA-positive blood donation.
Samples from the PDCS. A total of 14 children, RT-PCR positive for ZIKV and who experienced signs
and symptoms of Zika virus, from the Nicaraguan Pediatric Dengue Cohort Study (PDCS) were included.
The PDCS is a community-based prospective study of children 2 to 14 years of age that has been ongoing
since August 2004 in Managua, Nicaragua (43). Participants present at the first sign of illness to the
Health Center Sócrates Flores Vivas and are monitored daily during the acute phase of illness. Acute and
convalescent (14 to 21 days after onset of symptoms) blood samples are drawn for dengue, chikun-
gunya (CHIKV), and Zika virus diagnostic testing from patients meeting the case definition for dengue or
Zika virus (starting in January 2016) or presenting with undifferentiated febrile illness. In the PDCS, a
healthy blood sample is collected annually from participants; anti-DENV antibody titers are measured in
paired annual samples using enzyme-linked immunosorbent assay inhibition (EI) (44, 45), and infections
are defined by seroconversion or a 4-fold rise in anti-DENV titers. In this study, confirmed ZIKV cases
were classified as DENV naive if they entered the cohort study with no detectable anti-DENV antibodies
(as measured by EI) and had no documented DENV infections (symptomatic or inapparent) during their
time in the cohort. They were classified as DENV immune if they either entered the cohort with
detectable anti-DENV EI antibodies or entered the cohort study with no detectable anti-DENV antibodies
and had one or more documented DENV infections during their time in the cohort. All suspected ZIKV
cases were confirmed by RT-PCR in serum and/or urine using triplex assays that simultaneously screen
for DENV and CHIKV infections (ZCD assay [46], CDC Trioplexor and, in some cases, the CDC ZIKV
monoplex assay [20], in parallel with a DENV-CHIKV multiplex assay [47]). The PDCS was approved by the
IRB of the Nicaraguan Ministry of Health and the University of California, Berkeley. Parents or legal
guardians of all subjects provided written informed consent, and subjects 6 years old provided assent.
Samples from ZIKV-infected U.S. travelers. Blood samples of travelers were collected at the
University of North Carolina, University of Miami, Vanderbilt University, and the National Institutes of
Health from patients displaying symptoms of a suspected ZIKV infection following return to the United
States from areas where ZIKV is endemic. One donor had not traveled outside the United States and thus
locally acquired ZIKV infection in Miami, FL. All samples were screened for previous DENV exposure by
measuring DENV-specific serum IgG titers and/or neutralizing antibodies. Depending on the time of
sample collection postonset of symptoms, samples were classified as acute or convalescent as described
above.
PBMC isolation. PBMC were isolated by density-gradient sedimentation using Ficoll-Paque (Lym-
phoprep; Nycomed Pharma, Oslo, Norway) as previously described (10). Isolated PBMC were cryopre-
served in cell recovery media containing 10% dimethyl sulfoxide (DMSO) (Gibco), supplemented with 10
to 50% heat-inactivated fetal bovine serum (FBS; HyClone Laboratories, Logan UT), depending on the
processing laboratory, and stored in liquid nitrogen until use in the assays. PBMC collected in Sri Lanka
were stored in Synth-a-Freeze cryopreservation medium (A1254201; Thermo Fisher Scientific, USA).
Volunteers from the National Institutes of Health were enrolled into protocol VRC200 (ClinicalTrials
registration no. NCT00067054) and leukapheresed. PBMC were processed and cryopreserved as de-
scribed previously (48).
Serology. In general, DENV seropositivity was determined by DENV IgG or an inhibition ELISA, as
previously described (45, 49). Flow cytometry-based or Vero cell-based focus reduction neutralization
assays were performed for further characterization of positive donors, as previously described (50, 51).
RT-PCR assays for ZIKV determination. RNA was extracted from serum or urine using the QIAamp
viral RNA minikit (Qiagen). Samples were tested for ZIKV and/or DENV using the ZCD assay, as previously
described (46). DENV-positive samples were serotyped using a serotype-specific DENV multiplex assay
(46, 52). In some laboratories, samples were tested by RT-PCR for ZIKV as previously described (20). At the
Blood Systems Research Institute (BSRI), donors were identified as ZIKV RNA positive through routine
donor screening using the cobas Zika test (Roche Molecular Systems, Inc., Pleasanton, CA).
HLA typing. Donors were HLA typed by an ASHI-accredited laboratory at Murdoch University
(Western Australia) as previously described (11). HLA typing was performed for class I (HLA A, B, and C)
and class II (DQA1, DQB1, DRB1, and DPB1) using locus-specific PCR amplification on genomic DNA.
Primers used for amplification employed patient-specific barcoded primers. Amplified products were
quantitated and pooled by subject, and up to 48 subjects were pooled. An unindexed (454 technique,
8-lane runs) or indexed (8 indexed MiSeq technique runs) library then was quantitated using kappa
universal quantitative PCR library quantification kits. Sequencing was performed using either a Roche 454
FLX sequencer with titanium chemistry or an Illumina MiSeq using a 2-by-300 paired-end chemistry.
Reads were quality filtered and passed through a proprietary allele-calling algorithm and analysis
pipeline using the latest IMGT HLA allele database as a reference.
Major histocompatibility complex class I binding predictions and peptide selection. The
BeH818995 ZIKV isolate (GenBank accession no. AMA12084.1) was used to perform ZIKV peptide
selection. We selected a set of 9mer and 10mer ZIKV peptides predicted to bind one or more of 27 HLA
class I A and B allelic variants, which were chosen because of their high prevalence in the general
population, as previously described (10). Class I binding predictions were done with Tepitool using the
consensus method (53, 54). For each allele, and considering 9mers and 10mers separately, the top 2%
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scoring peptides (n 68) based on predicted percentile rank were selected; the final set synthesized had
1,836 (68 27) 9mers and 10mers each, for a total of 3,672 peptides (A&A, San Diego, CA). For screening
studies, the class I peptides were combined into pools of approximately 10 to 11 individual peptides
according to their predicted HLA restriction, resulting in approximately 13 pools per HLA allele. Table 1
lists the number of peptides synthesized for each allele as a function of protein of provenance. In
addition, we synthesized a panel of 15mer peptides, overlapping by 10 residues, spanning the entire
sequence of the ZIKV BeH818995 isolate. The sequence homology between ZIKV and DENV for each
protein is listed in Table 5. For screening studies, these peptides were combined into 10 megapools of
25 to 180 peptides according to the ZIKV protein from which they were derived (C, prM, E, NS1, NS2A,
NS2B, NS3, NS4A  2k, NS4B, and NS5). For deconvolution studies, positive peptide pools were
deconvoluted to identify individual epitopes, often going to an intermediate step of screening smaller
pools before the individual peptide tests. To assess DENV reactivity, pools of previously identified and
described DENV epitopes were utilized (i.e., DENV megapools [11, 28]).
IFN- ELISPOT assay. A total of 20  104 PBMC were incubated in triplicate with 0.1 ml complete
RPMI 1640 medium in the presence of peptide pools (1 g/ml) or individual peptides (10 g/ml).
Following 20 h of incubation at 37°C, the plates were incubated with biotinylated IFN- monoclonal
antibody (MAb 7-B6-1; Mabtech, Stockholm, Sweden) for 2 h and developed as previously described (10,
55). In CD4 experiments, CD8 cells were depleted before incubation using magnetic beads and positive
selection (MACS; Miltenyi Biotec, Auburn, CA). Cells from donors with PHA values below 250 spot-forming
cells (SFC)/106 PBMC have been excluded from the analysis.
Flow cytometry. Detailed information of all monoclonal antibodies used in this study are listed in
Table 6. For the intracellular cytokine staining, PBMC were cultured in the presence of HLA-matched
peptide pools (1 g/ml) and Golgi-Plug containing brefeldin A (BD Biosciences, San Diego, CA) for 6 h
and subsequently permeabilized, stained, and analyzed with the same monoclonal antibody panel as
that described previously (10). Cells from donors have been excluded from the analysis if the IFN-
response to phorbol myristate acetate and ionomycin stimulation was lower than 1% in the CD3 cells.
All data shown are background subtracted.
Statistical analysis. All statistical analyses were performed using the program Prism 7 (Graph-Pad
Software, San Diego, CA). Data are expressed as geometric means with 95% confidence intervals (CI) or
percentage of frequency, and data comparison was performed with Mann-Whitney or Fisher test,
respectively.
Accession number(s). Epitopes identified in this study have been submitted to the Immune Epitope
Database (IEDB; submission ID_1000720).
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